港股異動丨錦欣生殖漲4.44% 股價再創歷史新高
格隆匯11月4日丨錦欣生殖(01951.HK)漲4.44%,報15.04港元,股價再創歷史新高,成交7554萬港元,總市值約358億港元。

據格隆匯APP數據顯示,自從錦欣生殖被納入港股通標的以來,南下資金持續買入,最新持倉比例已達到2.34%。

天風證券上月發佈報告稱,公司輔助生殖行業市場空間大,護城河高,且在合規、規範、醫療質量與服務方面,軟硬實力兼備,屬於第一梯隊。因此,在估值上享有一定溢價,未來隨着產能的釋放,有望保持快速穩步的發展。公司通過成都西囡醫院,深圳中山醫院、美國HRC完成了在西南地區、華南地區以及美國地區的佈局。市場地位穩固,具有良好的增長潛力。另外,公司重視科研技術能力,擁有行業內知名的專家團隊,走在行業的前列。該行首次給予錦欣生殖"買入"評級,目標價15.24港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.